CTLA4 and cancer: Moreover, the clinical use of MAbs targeted for CTLA-4, PD1/PD-L1 (47), Staphylococcus aureus alpha-toxin (48), and respiratory syncytial virus (RSV) F-protein (49) has created broad prospects for the immunodiagnosis and immunotherapy of human malignant tumors and infectious diseases.